Unlike mast cell–mediated angioedema, patients with HAE-nC1INH show no response to high-dose H1 antihistamines, corticosteroids, epinephrine, leukotriene receptor antagonists, or omalizumab but may respond to KKS targeted treatments such as C1INH concentrates, bradykinin B2 receptor antagonists, or plasma kallikrein inhibitors (see treatment section below). The gene discussed is BDKRB2; the disease is angioedema.